SAN DIEGO, 13 September, 2016 - AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that company management will participate in two upcoming scientific and investor conferences:
• Rodman & Renshaw 18th Annual Global Investment Conference (September 11-13, New York) AmpliPhi CEO M. Scott Salka will present on Tuesday, September 13 from 4:15 to 4:40 p.m. EDT. Mr. Salka will discuss key corporate milestones in addition to reviewing AmpliPhi’s pipeline.
• Anti-Infectives Rx (September 21, Boston) AmpliPhi CEO M. Scott Salka will participate in a panel discussion titled “Tackling Resistance: The Promise and The Challenge” on September 21 from 9:00 to 9:30 a.m. EDT. For more information, visit www.ampliphibio.com.
